Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas (MarZoLyOss)

January 28, 2025 updated by: IRCCS Azienda Ospedaliero-Universitaria di Bologna

Retrospective Observational Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone Lymphomas

This is a purely retrospective and observational monocentric study

Study Overview

Status

Recruiting

Conditions

Detailed Description

the study aimed at describing the characteristics and outcome of Marginal zone lymphoma patients who were diagnosed and treated in our Hospital between December 2012 and December 2018

Study Type

Observational

Enrollment (Estimated)

160

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Marginal zone lymphoma patients who were diagnosed and treated in our Hospital between December 2012 and December 2018

Description

Inclusion Criteria:

  1. Marginal zone lymphoma patients who were diagnosed and treated in our Hospital between December 2012 and December 2018.
  2. Age ≥ 18 years at enrolment.
  3. Written informed consent (if applicable)

Exclusion Criteria:

  • none

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
clinical characteristics of Marginal zone lymphoma patients
Time Frame: through study completion, an average of 1 years
to descrive clinical characteristics of Marginal zone lymphoma patients who were diagnosed and treated in our Hospital.
through study completion, an average of 1 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
effectiveness
Time Frame: through study completion, an average of 1 years

It includes:

  1. Description of treatment duration and causes of treatment discontinuation.
  2. Description of adverse events / safety of the treatments
  3. Assessment of patients' survival.
  4. Description of the medical resource utilization, including number of emergency department visits, hospitalizations, use of hematopoietic growth factors and antibiotics, and blood product transfusions.
  5. Patient clinical and biological characteristics and disease biological profile at baseline of Marginal zone lymphoma cases
through study completion, an average of 1 years
safety
Time Frame: through study completion, an average of 1 years

It includes:

  1. Description of treatment duration and causes of treatment discontinuation.
  2. Description of adverse events / safety of the treatments
  3. Assessment of patients' survival.
  4. Description of the medical resource utilization, including number of emergency department visits, hospitalizations, use of hematopoietic growth factors and antibiotics, and blood product transfusions.
  5. Patient clinical and biological characteristics and disease biological profile at baseline of Marginal zone lymphoma cases
through study completion, an average of 1 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Investigators

  • Principal Investigator: Pier Luigi Zinzani, MD, IRCCS Azienda Ospedaliero-Universitaria di Bologna

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

May 1, 2025

Primary Completion (Estimated)

October 1, 2025

Study Completion (Estimated)

October 1, 2025

Study Registration Dates

First Submitted

December 3, 2024

First Submitted That Met QC Criteria

January 28, 2025

First Posted (Actual)

March 25, 2025

Study Record Updates

Last Update Posted (Actual)

March 25, 2025

Last Update Submitted That Met QC Criteria

January 28, 2025

Last Verified

October 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MarZoLyOss

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Marginal Zone B Cell Lymphoma

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe